Bolt Biotherapeutics, Inc. (BOLT)
After hours:
Chart Events
Performance Outlook
| Previous Close | 1.4600 |
| Open | 1.4400 |
| Bid | 1.4500 x 1100 |
| Ask | 1.4700 x 2200 |
| Day's Range | 1.4200 - 1.4727 |
| 52 Week Range | 1.1800 - 3.9900 |
| Volume | |
| Avg. Volume | 300,006 |
| Market Cap | 55.362M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.6360 |
| Earnings Date | Nov 10, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 5.00 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for BOLT
Related Research
- Bolt Biotherapeutics, Inc.Daily – Vickers Top Buyers & Sellers for 07/18/2022The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.RatingFair ValueEconomic Moat6 months agoArgus Research
- Simply Wall St.
Here's Why We're Watching Bolt Biotherapeutics' (NASDAQ:BOLT) Cash Burn Situation
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
- GlobeNewswire
Bolt Biotherapeutics Appoints Laura Berner to Board of Directors
REDWOOD CITY, Calif., Dec. 14, 2022 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today announced the appointment of Laura Berner to its Board of Directors effective Dec. 14, 2022. “Laura is an accomplished biopharmaceutical executive with impressive corporate leadership, operations, and business development experience,” said Randall Schatzman, Ph.D., Chief Executive Officer
- GlobeNewswire
Bolt Biotherapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update
– BDC-1001 dose-escalation clinical trial on track to complete recruitment by year-end 2022– BDC-3042 on track to enter the clinic in 2023; new preclinical data presented at SITC 2022– Cash balance of $209.6 million anticipated to fund key milestones through 2025 REDWOOD CITY, Calif., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today reported financial results
